Gujarat's First Terbium-161 FAPI PTRT Cancer Therapy Launched at Vadodara Hospital
In a landmark development for oncology care in Gujarat, the Bhailal Amin Cancer Centre in Vadodara has become the first facility in the state to introduce Terbium-161 FAPI PTRT (Peptide Targeted Radionuclide Therapy). This advanced nuclear medicine treatment represents a significant leap forward in improving outcomes for cancer patients, according to hospital officials.
A Major Advancement in Molecular Radiotheranostics
The therapy marks a substantial progression in the field of molecular radiotheranostics, which seamlessly integrates diagnosis and treatment into a unified approach. This innovative methodology offers a more precise and personalized strategy for cancer care, moving beyond traditional one-size-fits-all treatments.
Terbium-161 FAPI PTRT operates by delivering targeted radiation directly to cancer-associated fibroblasts within the tumour microenvironment. This sophisticated mechanism enables exceptionally accurate tumour targeting while significantly minimizing collateral damage to surrounding healthy tissues and organs.
Enhanced Effectiveness and Reduced Toxicity
Hospital authorities emphasize that this targeted approach substantially enhances treatment effectiveness, particularly for complex and treatment-resistant cancers that have proven challenging with conventional methods. The therapy is also associated with markedly lower toxicity levels compared to standard treatments, thereby improving patient tolerability and overall quality of life during and after treatment.
Dr Avani Jain, consultant in nuclear medicine and theranostics at the centre, explained that the treatment's precise targeting mechanism allows for effective destruction of tumour cells, including microscopic disease that might otherwise evade detection. "This technology preserves healthy tissue while aggressively attacking cancerous cells," she noted.
Broad Application Across Multiple Cancer Types
Dr Jain further elaborated that the therapy demonstrates considerable promise across numerous cancer types, including:
- Pancreatic cancer
- Sarcomas
- Cholangiocarcinoma
Additionally, emerging applications are being explored for breast, colorectal, gastrointestinal, and ovarian cancers, potentially expanding its therapeutic reach significantly.
Strengthening Personalized Oncology in Gujarat
Ravi Hirwani, president of Bhailal Amin General Hospital, stated that this introduction reflects a growing shift toward personalized and precision-based oncology in the region. "This initiative substantially strengthens our theranostics capabilities and reinforces our commitment to delivering advanced, patient-centric cancer care throughout Gujarat," he affirmed.
The implementation of Terbium-161 FAPI PTRT at the Vadodara facility positions Gujarat at the forefront of nuclear medicine innovation in India, offering new hope for patients facing difficult cancer diagnoses with previously limited treatment options.
